Daniel Faga is the President and CEO of AnaptysBio, a biopharmaceutical company focused on developing therapies for inflammatory diseases.
Daniel Faga is the President and CEO of AnaptysBio, a biopharmaceutical company focused on developing therapies for inflammatory diseases. As of April 20, 2026, Anaptys spun off its biopharma business, including its therapies, into a new company called First Tracks Biotherapeutics, with Faga leading the transition. He was previously appointed as Interim Chief Executive Officer of AnaptysBio before assuming the permanent CEO role.
Full founder directory · Investor directory · Company funding database · Fundraising library